The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cardiovascular Systems's revenues will grow 15.6% and EPS will remain in the red.
The average estimate for revenue is $21.6 million. On the bottom line, the average EPS estimate is -$0.33.
Last quarter, Cardiovascular Systems reported revenue of $22.9 million. GAAP reported sales were 5.5% higher than the prior-year quarter's $21.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.24. GAAP EPS were -$0.24 for Q4 compared to -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.4%, 320 basis points worse than the prior-year quarter. Operating margin was -17.4%, 1,550 basis points worse than the prior-year quarter. Net margin was -20.1%, 870 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $93.8 million. The average EPS estimate is -$1.15.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cardiovascular Systems is buy, with an average price target of $15.10.
- Add Cardiovascular Systems to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.